215 related articles for article (PubMed ID: 3987216)
1. Pharmacokinetics of ceftriaxone in subjects with renal insufficiency.
Kowalsky SF; Echols RM; Parker MA
Clin Pharm; 1985; 4(2):177-81. PubMed ID: 3987216
[TBL] [Abstract][Full Text] [Related]
2. Variability of ceftriaxone pharmacokinetics in hospitalized patients with severe infections.
Joos B; Luethy R; Muehlen E; Siegenthaler W
Am J Med; 1984 Oct; 77(4C):59-62. PubMed ID: 6093521
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacokinetics of cefotaxime in patients with chronic renal impairment (author's transl)].
Fillastre JP; Ings RM; Leroy A; Humbert G; Godin M
Nouv Presse Med; 1981 Feb; 10(8):574-9. PubMed ID: 6259595
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection.
Scully BE; Fu KP; Neu HC
Am J Med; 1984 Oct; 77(4C):112-6. PubMed ID: 6093511
[TBL] [Abstract][Full Text] [Related]
5. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
6. Doses of antibiotic in patients with renal insufficiency.
Ohkawa M; Kuroda K
Clin Ther; 1981; 4 Suppl A():124-32. PubMed ID: 6275994
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model.
Stoeckel K; Koup JR
Am J Med; 1984 Oct; 77(4C):26-32. PubMed ID: 6093514
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetics of cefotaxime and metabolites in uremic patients (author's transl)].
Fillastre JP; Ings RM; Leroy A; Godin M; Humbert G
Nephrologie; 1982; 3(1):12-8. PubMed ID: 6283411
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacokinetics of ceftriaxone in hemodialysis].
Laville M; Mercatello A; Freney J; Pozet N; Meugnier H; Labeeuw M; Fleurette J; Zech P
Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):719-23. PubMed ID: 3309803
[TBL] [Abstract][Full Text] [Related]
10. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment.
Matzke GR; Abraham PA; Halstenson CE; Keane WF
Clin Pharmacol Ther; 1985 Jul; 38(1):31-6. PubMed ID: 4006373
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of anakinra in subjects with different levels of renal function.
Yang BB; Baughman S; Sullivan JT
Clin Pharmacol Ther; 2003 Jul; 74(1):85-94. PubMed ID: 12844139
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD.
Kowalsky SF; Echols M; Schwartz MT; Bailie GR; McCormick E
Clin Nephrol; 1993 Jan; 39(1):53-8. PubMed ID: 8428409
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of norfloxacin in chronic renal failure.
Arrigo G; Cavaliere G; D'Amico G; Passarella E; Broccali G
Int J Clin Pharmacol Ther Toxicol; 1985 Sep; 23(9):491-6. PubMed ID: 4055162
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic profile of ceftriaxone in man.
Patel IH; Kaplan SA
Am J Med; 1984 Oct; 77(4C):17-25. PubMed ID: 6093513
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacokinetics of dibekacin in patients with chronic renal impairment].
Viotte G; Leroy A; Godin M; Fillastre JP
Nouv Presse Med; 1982 Nov; 11(46):3414-8. PubMed ID: 7155849
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of cefotaxime after a single intravenous dose in patients with impaired renal function.
Moukhtar I; Nawishy S; Sabbour M
Chemioterapia; 1987 Feb; 6(1):38-40. PubMed ID: 3829135
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetics of ceftriaxone in the first three month of life].
Rondanelli R; Regazzi MB; Stronati M; Calvi M; Lombardi G; Rondini G
Pediatr Med Chir; 1992; 14(1):55-9. PubMed ID: 1579518
[TBL] [Abstract][Full Text] [Related]
18. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
[TBL] [Abstract][Full Text] [Related]
19. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay.
Cheng JW; Charland SL; Shaw LM; Kobrin S; Goldfarb S; Stanek EJ; Spinler SA
Pharmacotherapy; 1997; 17(3):584-90. PubMed ID: 9165563
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
